Read our 2019 World Kidney Day email.
Bike to the Moon with the PKD Foundation of Canada from June 21-24, 2019!
ADPKD is the most common inherited renal disorder worldwide, impacting approximately 1 in every 500 Canadians. An estimated 45% to 70% of patients with ADPKD progress to end-stage renal disease by age 65 years.
Check out these 10 simple ways you can support your favourite nonprofits. They take less than five minutes and come at no cost!
On November 25, 2017 we held our biennial Canadian PKD Symposium, which included participants from the PKD medical community and various renal healthcare centres, as well as PKD patients, their families and loved ones.
Submitted by Chiara Gamberi, Ph. D.
Affiliate Assistant Professor, Department of Biology, Concordia University
We are pleased to share some encouraging news regarding the treatment landscape for those living with ADPKD. Today, Otsuka announced results from their Phase 3 REPRISE trial of tolvaptan in patients with autosomal dominant polycystic kidney disease (ADPKD). This data was presented at the American Society of Nephrology (ASN) Conference in New Orleans and published online in the New England Journal of Medicine.
We are glad to share some great news for the Canadian PKD community, as tolvaptan receives positive results from an additional one year international trial. The trial outcome was positive for tolvaptan in the treatment of ADPKD. Also of note, the trial had participation from Canadian patients and nephrologists.